ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO674

Peritoneal Dialysis After Renal Transplant Failure: A Different Beast Altogether

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Gama, Vivian, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
  • Ohman, Jakob David, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
  • Singh, Tripti, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
  • Astor, Brad C., University of Wisconsin, Madison, Wisconsin, United States
  • Waheed, Sana, University Of Wisconsin School Of Medicine and Public Health, Madison, Wisconsin, United States
Background

The number of patients starting dialysis after graft failure (DAGF) has been steadily increasing in the United States. This population differs significantly from those with native End Stage Renal Disease (ESRD) and little is known about the outcomes of DAGF patients on peritoneal dialysis (PD). We undertook this study to examine characteristics and survival of DAGF patients on PD compared to the native ESRD population on PD.

Methods

We analyzed the United States Renal Data System (USRDS) to assess characteristics and survival of DAGF and native ESRD patients on PD. Mortality rates were compared after adjustment for age, sex, number of comorbidities, and year of dialysis initiation.

Results

A total of 7.46% of DAGF and 7.09% of native ESRD patients used PD (p=0.01) and a total of 108,194 patients on PD were analyzed (Table 1). The mean age for DAGF patients on PD was significantly lower than native ESRD patients on PD (p<0.001). DAGF patients on PD were more likely to be employed than their counterparts with native ESRD (p<0.001). Those with DAGF had higher mortality than those with native ESRD (Table 2). This trend was even more significant after adjustment for age, sex, number of comorbidities, and year of dialysis initiation (p<0.001).

Conclusion

DAGF patients on PD have much worse outcomes compared to their native ESRD counterparts. The results of this study should encourage providers to consider DAGF PD patients as a high risk group and focus on risk reduction. Further research regarding the timing and cause of mortality in DAGF population on PD is needed.